Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04272515 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Molecular Characterization for Understanding Biliary Atresia

Study acronym: CAVB
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 22, 2026 (before its estimated August 7, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Feb 7, 2026 to Aug 7, 2026v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Mar 3, 2030 to Feb 7, 2026
    • Start date changed from estimate of Mar 3, 2020 to Feb 7, 2021
    • Study sites: 1 to 2
    • Study completion date: Mar 3, 2030 to Feb 7, 2032
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Although considered a rare disease, Biliary Atresia (BA) is the leading cause of neonatal cholestasis and liver transplantation in children. Little is known about the molecular mechanisms that drive BA. The purpose of this study is to collect the fluid samples, explanted liver tissue samples and dermal biopsy samples to enable investigators to perform the genetic and molecular analyses that might point to the gene(s) and cellular pathway involved in etiology of BA disease.
Trial Details
NCT Number NCT04272515
Lead Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Conditions
(from sponsor)		 Biliary Atresia
Related terms Biliary Atresia
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov